5-amino-1H-indole-3-acetonitrile | 26405-47-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-amino-1H-indole-3-acetonitrile
• 英文别名: 5-aminoindole-3-acetonitrile；5-Aminoindol-3-ylacetonitril；1H-Indole-3-acetonitrile, 5-amino-；2-(5-amino-1H-indol-3-yl)acetonitrile
• CAS: 26405-47-0
• 化学式: C₁₀H₉N₃
• 分子量: 171.202
• InChiKey: VBGAHRCLHMYZFJ-UHFFFAOYSA-N

物化性质

• 熔点：
  129-135 °C
• 沸点：
  464.6±30.0 °C(Predicted)
• 密度：
  1.313±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  65.6
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-amino-1H-indole-3-acetonitrile 在 RaNi 氨 作用下， 以 aq HOAc 、 水 为溶剂， 生成 N-[3-(2-aminoethyl)-1H-indol-5-yl]urea
  参考文献：
  名称：

  3-aminoalkyl-1H-indole-5-urea and amide derivatives

  摘要：

  用作抗高血压药物的化合物，其为3-氨基烷基-1H-吲哚-5-脲或酰胺衍生物，具有以下公式：##STR1##或其药用可接受的酸性加成盐，其中：R是C.sub.1-4低级烷基，C.sub.1-4低级烷氧基，苯基，##STR2##吡咯基，吡啶基或是由以下表示的取代氮：##STR3##其中R.sub.1是H或C.sub.1-4低级烷基或苯基或环烷基；R.sub.2是H或C.sub.1-4低级烷基；Y是H或卤素；R.sub.3是H或C.sub.1-4低级烷基；R.sub.4是H或C.sub.1-4低级烷基；R.sub.5是H或C.sub.1-4低级烷基或羧甲基或羧基三氟甲基；R.sub.6是H或C.sub.1-4低级烷基，且R.sub.5和R.sub.6也可以共同作为一个N-低级烷基-吡咯烷亚基。

  公开号：

  US04803218A1
• 作为产物：
  描述：

  5-硝基吲哚-3-乙腈 生成 5-amino-1H-indole-3-acetonitrile
  参考文献：
  名称：

  STANLEY, KERRY G.;HO, WINSTON

  摘要：

  DOI：

文献信息

• [EN] AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS<br/>[FR] DERIVES D'AZEPINOINDOLE ET DE PYRIDOINDOLE UTILISES COMME AGENTS PHARMACEUTIQUES
  申请人：X CEPTOR THERAPEUTICS INC

  公开号：WO2003099821A1

  公开（公告）日：2003-12-04

  The present invention is directed to compounds of formula (I) and formula (II): formula (I) and (II), wherein R1-R8, A and n are as described in the description. These compounds are used in pharmaceutical compositions and methods for modulating the activity of orphan nuclear receptors.

  本发明涉及化合物的公式（I）和公式（II）：公式（I）和（II），其中R1-R8，A和n如描述中所述。这些化合物用于制备药物组合物，并用于调节孤儿核受体的活性的方法。
• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060113A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种具有公式（I）的新化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• Azepinoindole derivatives as pharmaceutical agents
  申请人：Busch Brett

  公开号：US20050054634A1

  公开（公告）日：2005-03-10

  Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

  提供了用于调节受体活性的化合物、组合物和方法。具体来说，提供了用于调节受体活性以及用于治疗、预防或改善与受体活性直接或间接相关的一种或多种疾病或紊乱症状的化合物和组合物。
• 5-substituted 3-aminoalkyl indoles
  申请人：Glaxo Group Limited

  公开号：US04839377A1

  公开（公告）日：1989-06-13

  Compounds are disclosed of general formula (I) ##STR1## wherein R.sub.1 represents a group CHO, COR.sub.8, CO.sub.2 R.sub.8, CONR.sub.9 R.sub.10, CSNR.sub.9 R.sub.10 or SO.sub.2 NR.sub.9 R.sub.10, where R.sub.8 represents an alkyl, cycloalkyl, aryl or aralkyl group, R.sub.9 represents a hydrogen atom or an alkyl group, and R.sub.10 represents a hydrogen atom or an alkyl, cyclo-alkyl, aryl or aralkyl group; R.sub.2, R.sub.3, R.sub.4, R.sub.6 and R.sub.7, which may be the same or different, each represents a hydrogen atom or a C.sub.1-3 alkyl group; R.sub.5 represents a hydrogen atom or an alkyl, cycloalkyl, alkenyl or an aralkyl group or R.sub.4 and R.sub.5 together form an aralkylidene group or R.sub.4 and R.sub.5 together with the nitrogen atom to which they are attached form a saturated monocyclic 5- to 7-membered ring; and Alk represents an alkylene chain containing two or three carbon atoms which may be unsubstituted or substituted by not more than two C.sub.1-3 alkyl groups; with the provisos that when R.sub.4 and R.sub.5 both represent alkyl groups R.sub.1 does not represent the group CHO or COR.sub.8 and that when R.sub.4, R.sub.5, R.sub.6 and R.sub.7 all represent hydrogen R.sub.1 does not represent the group SO.sub.2 NH.sub.2 ; and physiologically acceptable salts, solvates and bioprecursors thereof. The components are described as potentially useful for the treatment of migraine and may be formulated as pharmaceutical compositions in convention manner using one or more pharmaceutically acceptable carriers or excipients. Various processes for the preparation of the compounds are disclosed including, for example, reaction of an aminoalkyl indole with an acid of formula R.sub.1 OH or an acylating agent corresponding thereto or with an inorganic cyanate or an organic isocyanate or isothiocyanate in order to introduce the desired R.sub.1 group at the 5-position on the indole nucleus.

  揭示了一般式(I)的化合物 ##STR1## 其中R.sub.1代表CHO基团、COR.sub.8基团、CO.sub.2R.sub.8基团、CONR.sub.9R.sub.10基团、CSNR.sub.9R.sub.10基团或SO.sub.2NR.sub.9R.sub.10基团，其中R.sub.8代表烷基、环烷基、芳基或芳基烷基，R.sub.9代表氢原子或烷基基团，R.sub.10代表氢原子或烷基、环烷基、芳基或芳基烷基；R.sub.2、R.sub.3、R.sub.4、R.sub.6和R.sub.7，可能相同也可能不同，每个代表氢原子或C.sub.1-3烷基基团；R.sub.5代表氢原子或烷基、环烷基、烯基或芳基烷基基团或R.sub.4和R.sub.5一起形成芳基烷基亚基团或R.sub.4和R.sub.5与其连接的氮原子一起形成饱和的单环5-至7-成员环；Alk代表含有两个或三个碳原子的烷基链，可以是未取代的或被不超过两个C.sub.1-3烷基基团取代；但是，当R.sub.4和R.sub.5都代表烷基基团时，R.sub.1不代表CHO基团或COR.sub.8基团，当R.sub.4、R.sub.5、R.sub.6和R.sub.7都代表氢原子时，R.sub.1不代表SO.sub.2NH.sub.2基团；以及其生理上可接受的盐、溶剂和生物前体。这些成分被描述为潜在用于治疗偏头痛的，并且可以制备为药物组成物，在常规方法中使用一个或多个药学上可接受的载体或赋形剂。揭示了包括化合物制备的各种过程，例如，将氨基烷基吲哚与一般式R.sub.1OH的酸或相应的酰化剂或与无机氰酸酯或有机异氰酸酯或异硫氰酸酯反应，以在吲哚核上的5位引入所需的R.sub.1基团。
• [EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060112A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及具有式（I）的新化合物，其能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗多种疾病。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。